GD2-directed bispecific trifunctional antibody outperforms dinutuximab beta in a murine model for aggressive metastasized neuroblastoma

GD2-directed bispecific trifunctional antibody outperforms dinutuximab beta in a murine model for aggressive metastasized neuroblastoma

Background Neuroblastoma is the most common extracranial solid tumor of childhood. Patients with high-risk disease undergo extremely aggressive therapy and nonetheless have cure rates below 50%. Treatment with the ch14.18 monoclonal antibody (dinutuximab beta), directed against the GD2 disialogangli...

Full description

Bibliographic Details
Main Authors: Annette Künkele, Angelika Eggert, Johannes H Schulte, Anika Klaus, Horst Lindhofer, Felix Zirngibl, Sara M Ivasko, Laura Grunewald, Silke Schwiebert, Peter Ruf, Kathy Astrahantseff, Lena Andersch, Holger N Lode, Kathleen Anders, Patrick Hundsdoerfer
Format: Article
Language:English
Published: BMJ Publishing Group 2021-07-01
Series:Journal for ImmunoTherapy of Cancer
Online Access:https://jitc.bmj.com/content/9/7/e002923.full

Internet

https://jitc.bmj.com/content/9/7/e002923.full

Similar Items